Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Bishoy Morris Faltas"'
Autor:
Himanshu Nagar, Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy Morris Faltas, Arshin Sheybani, Shiva Baghaie, Lawrence Howard Schwartz, David E. Kozono, Jeffrey A Bogart, Olivia Conway, Gina L. Mazza, Ronald C. Chen, Andrew Leonard Laccetti, Jonathan E. Rosenberg, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 41:TPS589-TPS589
TPS589 Background: In patients (pts) with metastatic unresectable urothelial cancer, platinum-based chemotherapy remains the standard of care for first-line treatment followed by switch maintenance avelumab if disease control is achieved with chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fcb9e603dfb909ce3eed21dd5f8fdae
https://doi.org/10.1200/jco.2023.41.6_suppl.tps589
https://doi.org/10.1200/jco.2023.41.6_suppl.tps589
Autor:
Kyrillus Samaan Shohdy, Dario Martin Villamar, Yen Cao, Janson Trieu, Kristin Sedgwick Price, Rebecca Nagy, Scott T. Tagawa, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Petros Grivas, Guru P. Sonpavde, Juan Miguel Mosquera, Olivier Elemento, Nicholas J. Vogelzang, Bishoy Morris Faltas
Publikováno v:
Journal of Clinical Oncology. 40:532-532
532 Background: It is not known whether serial circulating tumor DNA (ctDNA) can augment imaging for assessing treatment response in patients (pts.) with advanced urothelial carcinoma (UC). We hypothesized that serial ctDNA measurements predict the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68f04849ce9c0775c50dd24657ebd848
https://doi.org/10.1200/jco.2022.40.6_suppl.532
https://doi.org/10.1200/jco.2022.40.6_suppl.532